Developing new metal-based therapeutics: challenges and opportunities
- PMID: 17992277
- DOI: 10.1039/b706075k
Developing new metal-based therapeutics: challenges and opportunities
Abstract
Unexpected side effects and problems experienced in clinical trials have created a difficult environment for those developing new pharmaceuticals and, as a consequence, the number of new chemical entities being registered has fallen to a historic low. Those developing metal-based therapeutics will face the same difficulties, but this environment also provides many opportunities for creative solutions to be applied to overcoming the problems and concerns. In this perspective, these challenges and opportunities are considered in the context of examples of a number of classes of metal-based therapeutics.
Similar articles
-
Metal based drugs: from serendipity to design.Dalton Trans. 2007 Nov 21;(43):4903-17. doi: 10.1039/b705551j. Epub 2007 Sep 19. Dalton Trans. 2007. PMID: 17992275 Review.
-
Chemistry. Metal-based therapeutics.Science. 2007 Nov 30;318(5855):1392-3. doi: 10.1126/science.1150504. Science. 2007. PMID: 18048674 No abstract available.
-
New approaches for medicinal applications of bioinorganic chemistry.Curr Opin Chem Biol. 2007 Apr;11(2):115-20. doi: 10.1016/j.cbpa.2007.01.012. Epub 2007 Feb 2. Curr Opin Chem Biol. 2007. PMID: 17276132 Review.
-
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Food Chem Toxicol. 2008. PMID: 18328408 Review.
-
Opportunities and challenges in the discovery of new central nervous system drugs.Ann N Y Acad Sci. 2008 Nov;1144:243-50. doi: 10.1196/annals.1418.024. Ann N Y Acad Sci. 2008. PMID: 19076381
Cited by
-
Binding of Organometallic Ruthenium Anticancer Complexes to DNA: Thermodynamic Base and Sequence Selectivity.Int J Mol Sci. 2018 Jul 23;19(7):2137. doi: 10.3390/ijms19072137. Int J Mol Sci. 2018. PMID: 30041439 Free PMC article.
-
Mixed Ligand Mononuclear Copper(II) Complex as a Promising Anticancer Agent: Interaction Studies with DNA/HSA, Molecular Docking, and In Vitro Cytotoxicity Studies.ACS Omega. 2022 Jun 13;7(25):21961-21977. doi: 10.1021/acsomega.2c02354. eCollection 2022 Jun 28. ACS Omega. 2022. PMID: 35785271 Free PMC article.
-
Synthesis of Ni(II) complexes bearing indole-based thiosemicarbazone ligands for interaction with biomolecules and some biological applications.J Biol Inorg Chem. 2017 Jun;22(4):461-480. doi: 10.1007/s00775-016-1424-1. Epub 2016 Dec 19. J Biol Inorg Chem. 2017. PMID: 27995332
-
Cellular up-regulation of Nedd4 family interacting protein 1 (Ndfip1) using low levels of bioactive cobalt complexes.J Biol Chem. 2011 Mar 11;286(10):8555-8564. doi: 10.1074/jbc.M110.203448. Epub 2010 Dec 27. J Biol Chem. 2011. PMID: 21187286 Free PMC article.
-
The outcast of medicine: metals in medicine--from traditional mineral medicine to metallodrugs.Front Pharmacol. 2025 Apr 7;16:1542560. doi: 10.3389/fphar.2025.1542560. eCollection 2025. Front Pharmacol. 2025. PMID: 40260378 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources